Avid Bioservices Announces Proposed Private Placement of Convertible Notes
March 06, 2024 16:32 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it...
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
March 06, 2024 16:31 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
December 07, 2023 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $25.4 Million -- -- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million -- -- Entered into Partnership with California...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
November 30, 2023 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
November 08, 2023 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility
October 17, 2023 08:05 ET
|
Avid Bioservices, Inc
Avid completes construction of cell and gene theapy facility bringing total revenue generating capacity to up to ~$400 Million annually
Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference
September 26, 2023 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023
September 07, 2023 16:05 ET
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
August 31, 2023 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023
June 21, 2023 16:07 ET
|
Avid Bioservices, Inc
-- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Million in Net New Business Orders Resulting in a...